- monatlichErscheinungsrhythmus
- 31 mintypische Länge
- 22. Okt.letzte Folge
McKinsey colleagues Alex Devereson and Nav Nagra explore cutting-edge technology trends, tackle pressing industry challenges, and uncover R&D innovations with biopharma leaders. Whether you're a seasoned professional or a curious enthusiast, this series offers valuable insights and thought-provoking discussions that will keep you informed and inspired. Tune in and stay ahead of the curve in the ever-evolving world of biopharma.
Folgen
Pfizer’s Alex Condoleon on medical affairs accountability
Pfizer’s chief medical affairs officer talks about measuring medical affairs’ true impact, leading change at scale, and what patient-first really means. See https://www.mckinsey.com/privacy-policy for privacy information
Novartis’s Christian Diehl on scaling AI beyond the demo
Novartis’s chief data and digital officer for biomedical research explains how data platform investments are paying off in AI safety prediction, generative chemistry, and faster translation See https://www.mckinsey.com/privacy-policy for pr
AstraZeneca's Bob Li on the MARS mission to eliminate cancer
Bob Li, AstraZeneca's Senior Vice President, Global Head of Medical Affairs, Oncology, on why only seven percent of cancer patients get access to clinical trials, and what decentralized trials, AI, and international collaboration could do t
McKinsey’s Fangning Zhang on China’s growing role in life sciences R&D
McKinsey partner Fangning Zhang discusses what’s driving China’s acceleration in drug discovery, why intense competition is fueling speed and cost efficiency, and what global R&D leaders need to do to build a genuine China strategy. See htt
Bayer’s Sai Jasti on driving productivity in R&D with data science and AI
Bayer’s Senior Vice President and Head of Data Science and AI, Sai Jasti, on how the company is transforming its workflows and embedding AI in research and development to meet ambitious productivity goals. See https://www.mckinsey.com/priva
Bristol Myers Squibb CDTO Greg Meyers on biopharma’s AI-enabled future
Greg Meyers, Executive Vice President and Chief Digital & Technology Officer at Bristol Myers Squibb (BMS) discusses how technology can be leveraged to drive outcomes. See https://www.mckinsey.com/privacy-policy for privacy information
Lykke Hinsch Gylvin on the cutting edge of clinical trial design
Lykke Hinsch Gylvin shares how Boehringer Ingelheim’s innovative clinical trial designs bring therapies to patients faster. See https://www.mckinsey.com/privacy-policy for privacy information
Genentech’s John Marioni on enhancing drug discovery with data and AI
John Marioni discusses how he and his teams across industries and academia use evolving technologies to bring sophisticated drug therapies to patients. See https://www.mckinsey.com/privacy-policy for privacy information
J&J’s Ashita Batavia on advancing oncology clinical-trials with data
In this episode of Eureka!, a McKinsey podcast on innovation in life sciences R&D, hosts Navraj Nagra, Alex Devereson, and Meredith Langstaff speak to Ashita Batavia, head of hematology and oncology data sciences, R&D, at Johnson & Johnson
GSK's Kim Branson on driving innovation with AI and machine learning
In this episode, hosts Navraj Nagra and Alex Devereson speak to Kim Branson, senior vice president and global head of AI and machine learning at GSK. They discuss how these emerging technologies are being used to potentially reshape how dru
AbbVie’s head of genomics research on the transformative power of AI
In this episode, Howard Jacob, AbbVie’s vice president of genomics research and head of data integration, discusses early adoption of data integration at AbbVie, the challenges of medical silos, and the steps needed to build novel AI and ma
Advancing R&D for chronic diseases with AI: A conversation with Novo Nordisk’s CSO
Marcus Schindler, chief scientific officer, and head of research and early development at Novo Nordisk, shares the ways in which he's leading the company’s efforts to embrace external innovation and expand into new therapeutic areas with AI
